Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9706 USD | +1.78% | -1.99% | -29.67% |
Mar. 27 | Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating | MT |
Mar. 27 | Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company appears to be poorly valued given its net asset value.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.67% | 187M | C | ||
-0.49% | 105B | B+ | ||
+3.31% | 97.5B | B+ | ||
+2.30% | 22.19B | B | ||
-16.16% | 21.33B | B+ | ||
-7.38% | 18.68B | A- | ||
-41.41% | 16.6B | A- | ||
-22.87% | 14.52B | B | ||
+6.32% | 14.09B | C+ | ||
+21.46% | 10.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BLUE Stock
- Ratings bluebird bio, Inc.